NewsRoom Articles - Page 569 of 1390

TuesdaySep 01, 2020 1:20 pm

Helius Medical Technologies Inc. (NASDAQ: HSDT) (TSX: HSM) Starts Presentation at The LD 500

Helius Medical Technologies Inc. (NASDAQ: HSDT) (TSX: HSM) is a neurotech company in the medical device industry that is focused on neurological wellness. The company's purpose is to develop, license and acquire unique and noninvasive platform technologies that amplify the brain's ability to heal itself. The company's first commercial product is the Portable Neuromodulation Stimulator (PoNS(TM)). For more information, visit the company's website at www.heliusmedical.com About The LD 500 The LD 500 is the most ambitious project in LD Micro's 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that…

TuesdaySep 01, 2020 1:20 pm

Genprex Inc. (NASDAQ: GNPX) Starts Presentation at The LD 500

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). In January 2020, the U.S. Food…

TuesdaySep 01, 2020 1:20 pm

Driven Deliveries Inc. (OTCQB: DRVD) Starts Presentation at The LD 500

Driven Deliveries Inc. (OTCQB: DRVD) is one of California's fastest-growing online cannabis retailers and direct-to-consumer logistics companies. Driven is one of the first publicly traded cannabis delivery services operating within the United States. Founded by experienced technology and cannabis executives, the company provides e-commerce solutions, online sales and on-demand cannabis delivery in select cities where allowed by law. Driven offers legal cannabis consumers the ability to purchase and receive their marijuana in a fast and convenient manner. By leveraging consumer trends and offering a proprietary, turnkey delivery system to its customers, management believes it is uniquely positioned to best serve…

TuesdaySep 01, 2020 1:20 pm

AIM ImmunoTech Inc. (NYSE American: AIM) Starts Presentation at The LD 500

AIM ImmunoTech Inc. (NYSE American: AIM) is an immuno-pharma company focused on the research and development of new therapeutics to treat seriously debilitating immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include Argentina-approved drug rintatolimod (trade names Ampligen(R) or Rintamod(R)) and FDA-approved drug Alferon N Injection(R). Uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA candidate being developed for globally important debilitating diseases and disorders of the immune system. For more information, visit the company's website at www.aimimmuno.com About…

TuesdaySep 01, 2020 1:03 pm

Trxade Group, Inc. (NASDAQ: MEDS) to Boost Brand Through Participation in LD 500 Virtual Investor Conference

Trxade Group Inc. is a supplies and services innovator for the pharmaceutical industry, working to keep small retailers competitive with large chains and costs accessible for end-use patients Trxade Group has seen its brand grow significantly during the past year, adding a 244 percent year-over-year increase to its quarterly revenues during the spring The company will further draw attention to its profile by joining other brand presentations at the LD 500 Virtual Investor Conference scheduled to begin Sept. 1 and run through the week The LD 500 conference is designed to provide an online-accessible meeting of small cap companies and…

TuesdaySep 01, 2020 1:00 pm

Arch Therapeutics Inc. (OTCQB: ARTH) Starts Presentation at The LD 500

Arch Therapeutics Inc. (OTCQB: ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G and AC5 Surgical Hemostat. The U.S. Food and Drug Administration (FDA) has provided clearance to market AC5(R) Topical Gel to be used in the management of partial and full-thickness wounds, such as pressure sores,…

TuesdaySep 01, 2020 1:00 pm

EnviroLeach Technologies Inc. (CSE: ETI) (OTCQB: EVLLF) Starts Presentation at The LD 500

EnviroLeach Technologies Inc. (CSE: ETI) (OTCQB: EVLLF) is engaged in the development and commercialization of environmentally friendly formulas and technologies for the treatment of materials in the mining and recycling sectors. Using its proprietary non-cyanide, water-based, neutral pH treatment process, EnviroLeach extracts precious metals from ores, concentrates and e-waste using only FDA-approved additives and ambient temperature water. Backed by the momentum of a first-class staff of scientists and engineers, tens of thousands of individual assays, independent validations, strategic partners and over $20 million in research and development, EnviroLeach's technology is emerging as a potential new standard for the provision of…

TuesdaySep 01, 2020 1:00 pm

Kindred Biosciences Inc. (NASDAQ: KIN) Starts Presentation at The LD 500

Kindred Biosciences Inc. (NASDAQ: KIN) is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio. For more information, visit the…

TuesdaySep 01, 2020 1:00 pm

ReneSola Ltd. (NYSE: SOL) Starts Presentation at The LD 500

ReneSola Ltd. (NYSE: SOL) is a leading global solar project developer and operator. The company focuses on solar power project development, construction management and project financing services. With local professional teams in more than 10 countries around the world, the business is spread across many regions where solar power project markets are growing rapidly and can sustain that growth due to improved clarity around government policies. The company's strategy is to pursue high-margin project development opportunities in these profitable and growing markets, specifically in the U.S. and Europe, where the company has a market-leading position in several geographies, including Poland,…

TuesdaySep 01, 2020 12:41 pm

RedHill Biopharma Ltd. (NASDAQ: RDHL) Featured in Virtual Coverage of The Wall Street Investor Forum

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers’ diarrhea in adults. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; (iii) RHB-104,…